Cargando…
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC). The subjects were histopathologically proven APC...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361829/ https://www.ncbi.nlm.nih.gov/pubmed/15942632 http://dx.doi.org/10.1038/sj.bjc.6602644 |